Protective effect of lactulose on dextran sulfate sodium-induced colonic inflammation in rats

Digestive Diseases and Sciences

Volumn 49, Issue 9, 2004, Pages 1466-1472

  Rumi, György ^a   Tsubouchi, Ryouichi ^a   Okayama, Mitsuaki ^a   Kato, Shinichi ^a   Mózsik, Gyula ^b   Takeuchi, Koji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

experimental colitis; lactulose; prebiotics; prophylactic effect; rat

Indexed keywords

DEXTRAN SULFATE; LACTULOSE; MESALAZINE; MYELOPEROXIDASE; PROBIOTIC AGENT; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT DISORDER; COLON MUCOSA; COLON ULCER; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; HEMATOCHEZIA; HISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RAT; RAT STRAIN; ULCERATIVE COLITIS;

ANIMALS; BIOPSY, NEEDLE; COLITIS, ULCERATIVE; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; INTESTINAL MUCOSA; LACTULOSE; LIPID PEROXIDATION; MALE; PEROXIDASE; PROBABILITY; PROTECTIVE AGENTS; RATS; RATS, WISTAR; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 4644338124     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DDAS.0000042248.48819.ad     Document Type: Article

References (35)

1. Farrel RJ, Peppercorn MA: Ulcerative colitis. Lancet 359:331-340, 2002
2. Borody TJ, Warren EF, Leis S, Surace R, Ashma O: Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 37:42-47, 2003
3. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T: Randomized control trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 22:56-63, 2003
4. Hart AL, Stagg AJ, Kamm MA: Use of probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 36:11-19, 2003
5. Heller F, Duchmann R: Intestinal flora and mucosal immune responses. Int J Med Microbiol 293:77-86, 2003
6. Elson CO, Sartor RB, Tennyson GS, Riddell RH: Experimental models of inflammatory bowel disease. Gastroenterology 109:1344-1367, 1995
7. Shanahan F: Probiotics and inflammatory bowel disease: Is there a scientific rationale? Inflamm Bowel Dis 6:107-115, 2000
8. Fujiwara M, Kaneko T, Iwana H, Taketomo N, Tsunoo H, Kanno J, Ohkusa T, Okayasu I: Inhibitory effects of bifidobacterium longum on experimental ulcerative colitis induced in mice by synthetic dextran sulfate sodium. Digestion 67:90-95, 2003
9. Kanauchi O, Serizawa I, Araki Y, Suzuki A, Andoh A, Fujiyama I, Mitsuyama K, Takaki K, Toyonaga A, Sata M, Bamba T: Germinated barley foodstoff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment. J Gastroenterol 38:134-141, 2003
10. Schultz M, Veltkamp C, Dieleman LA, Grenther WB, Wyrick PB, Tonkonogy SL, Sartor RB: Lactobacillus plantarum 299Vs in the treatment and prevention of spontaneous colitis in interleukin 10-deficient mice. Inflamm Bowel Dis 8:71-80, 2002
11. Rembacken BJ, Snelling AM, Hawkey PM, Axon ATR: Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet 354:635-639, 1999
12. Venturi A, Gionchetti P, Rizello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, Campieri M: Impact on the faecal flora composition of a new probiotic preparation. Preliminary data on maintenance treatment of patients with ulcerative colitis (UC) intolerant or allergic to 5 aminosalicylic acid (5-ASA). Aliment Pharmacol Ther 13:1103-1108, 1999
13. Guslandi M, Mezzi G, Sorghi M, Testoni PA: Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 45:1462-1464, 2000
14. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M: Prophylaxis of pouchitis onset with with probiotic therapy: a double blind, placebo-controlled trial. Gastroenterology 124:1202-1209, 2003
15. Kanauchi O, Mitsuyama K, Araki Y, Andoh A: Modification of intestinal flora in the treatment of inflammatory bowel disease. Curr Pharm Res 9:333-346, 2003
16. Bezkorovainy A: Probiotics: determinants of survival in the gut. Am J Clin Nutr 73:399-405, 2001
17. Madsen K: The use of probiotics in gastrointestinal disease. Can J Gastroenterol 15:817-822, 2001
18. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN: Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 116:1107-1114, 1999
19. Szilagyi A, Rivard J, Shrier I: Diminished efficacy of colonic adaptation to lactulose occurs in patients with inflammatory bowel disease in remission. Dig Dis Sci 47:2811-2822, 2002
20. Krawisz JE, Sharon P, Stenson WF: Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity: assessment of inflammation in rat and hamster models. Gastroenterology 87:1344-1350, 1984
21. Ohkawa H, Ohishi N, Yagi K: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351-358, 1979
22. Grisham MB, Granger DN: Neutrophil-mediated mucosal injury; role of oxygen metabolites. Dig Dis Sci 33:S6-S13, 1988
23. Yoshida N, Yoshikawa T, Yamaguchi T, Naito Y, Tanigawa T, Murase H, Kondo M: A novel water-soluble vitamin E derivative protects against experimental colitis in rats. Antiox Redox Signal 1:555-562, 1999
24. Schumann C: Medical, nutritional and technological properties of lactulose. An update. Eur J Nutr 41:17-25, 2002
25. Hoffmann K, Mossell DAA, Korus W, van de Kamer JH: Investigations on the mode of action of lactulose in the human intestine. Klin Wochenschr 42:126-130, 1964
26. Johansson ML, Molin G, Jeppsson B, Nobaek S, Ahrne S, Bengmark S: Administration of different lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect of the indigenous flora. Appl Environ Microbiol 59:15-20, 1993
27. Hartley MG, Hudson MJ, Swarbride ET: The rectal mucosal-associated micro flora in patients with ulcerative colitis. J Med Microbiol 36:96-104, 1992
28. Sartor RB: Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 24:475-507, 1995
29. Fabia R, Ar'Rajab A, Johansson M-L, Willen R, Andersson R, Molin G, Bengmark S: The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat. Scand J Gastroenterol 28:155-162, 1993
30. Mao Y, Nobaek S, Kasravi B, Adawi D, Stenram U, Molin G, Jeppsson B: The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. Gastroenterology 111:334-344, 1996
31. Kruis W, Schuts E, Fric P, Fixa B, Judmaier G, Stolte M: Double-blind comparison of an oral Escerichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11:853-858, 1997
32. Axelsson LT, Chung TC, Dobrogosz WJ, Lindgren SE: Production of a broad spectrum antimicrobial substance by Lactobacillus reuteri. Microb Ecol Health Dis 2:131-136, 1989
33. Kaila M, Isolauri E, Soppi E, Virtanen E, Laine S, Arvilommi H: Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res 32:141-144, 1992
34. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C: Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121:580-591, 2001
35. Ulisse S, Gionchetti P, D'Alo S, Russo FP, Pesce I, Ricci G, Rizello F, Helwig U, Cifone MG, Campieri M, De Simone C: Expression of cytokines, inducible nitric oxide synthetase and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 96:2691-2699, 2001